United States Food and Drug Administration (USFDA) has completed inspection at Lupin’s Aurangabad, India facility. The inspection was carried out between February 10, 2020 and February 14, 2020. The inspection concluded without any observation.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.